This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| MOG | |
|---|---|
| Name | MOG |
| Classification | Protein |
| Gene | MOG gene |
| Located | Central nervous system |
MOG
Myelin oligodendrocyte glycoprotein is a central nervous system surface glycoprotein first characterized in studies of myelin and oligodendrocytes. It has been investigated across disciplines including neurology, immunology, and molecular biology, and it features in research on demyelinating diseases, neuroimmunology, and biomarker development. MOG-related research intersects with work from institutions such as the National Institutes of Health, University of Cambridge, Harvard Medical School, and Karolinska Institutet.
The protein is often referred to by the gene symbol from the human locus on chromosome 6, and literature from groups at Johns Hopkins, Stanford University, and University College London uses consistent nomenclature in biochemical and immunopathological contexts. Historical descriptions appear alongside classical myelin studies from researchers at Institut Pasteur, Max Planck Institute, and University of Oxford. Terminology in review articles by authors affiliated with Mayo Clinic, Columbia University, and University of Toronto distinguishes the protein from other myelin antigens such as those described in work at Rockefeller University and University of Pennsylvania. Debates in nomenclature have been discussed at conferences hosted by the World Health Organization and European Academy of Neurology.
MOG is a single-pass membrane glycoprotein expressed on the outermost lamellae of the myelin sheath produced by oligodendrocytes; structural analyses have been published by groups at Massachusetts Institute of Technology, ETH Zurich, and Technical University of Munich. X-ray crystallography and cryo-electron microscopy studies from laboratories at Yale University, University of California San Francisco, and Northwestern University describe an immunoglobulin-like extracellular domain, short transmembrane region, and intracellular tail, with glycosylation patterns characterized by teams at University of Chicago and University of British Columbia. Comparative genomics from researchers at University of Edinburgh, Kyoto University, and Australian National University highlight conservation across mammalian species including mouse models from Jackson Laboratory and rat models from Karolinska Institutet. Protein interaction maps produced by scientists at Broad Institute and European Molecular Biology Laboratory link MOG to components of the myelin sheath studied alongside proteolipid protein described by investigators at Baylor College of Medicine and myelin basic protein characterized by researchers at University of Freiburg.
Functional roles have been proposed based on studies at Stanford, University of Pennsylvania, and University of California Los Angeles implicating the protein in myelin sheath integrity, axon-myelin interactions, and cellular adhesion mediated by extracellular domains. Developmental expression profiles from Harvard Medical School, University of Michigan, and Columbia University indicate peak expression during oligodendrocyte maturation and CNS myelination phases identified in developmental neuroscience literature from University of Washington and University of Sydney. Electrophysiological and imaging studies at Cleveland Clinic, McGill University, and University of Bonn suggest roles in regulating nodal architecture and in responses to injury, aligning with animal model work from University of Geneva and Max Delbrück Center.
Autoantibodies targeting the protein have been associated with inflammatory demyelinating syndromes investigated at Mayo Clinic, King's College London, and Charité – Universitätsmedizin Berlin. Clinical cohorts from Johns Hopkins, University of California San Diego, and Italian multicenter studies report associations between seropositivity and presentations overlapping with disorders studied by clinicians at Mount Sinai Hospital and University Hospital Zurich. Differential diagnosis considerations reference disorders described in literature from Cleveland Clinic Foundation and University of Texas Southwestern, with epidemiological data contributed by teams at University of Oslo and University of Helsinki. Case series published by Imperial College London and University of Melbourne examine optic neuritis, transverse myelitis, and encephalitic presentations compared alongside pathology described by investigators at Institut Curie and Hospital Clínic de Barcelona.
Diagnostic assays have been developed using cell-based assays and immunoassays by laboratories at Leiden University Medical Center, University of Freiburg, and University of Antwerp; these methods complement neuroimaging protocols from Massachusetts General Hospital, Charité, and Royal London Hospital. Biomarker studies integrate cerebrospinal fluid analysis techniques established at Stanford, University College London, and University of Bern, and adopt antibody detection platforms refined at Scripps Research and Ragon Institute. Multicenter validation efforts involve collaborations with European Federation of Neurological Societies, American Academy of Neurology, and International Pediatric MS Study Group.
Therapeutic approaches are informed by immunotherapy trials and treatment guidelines developed by teams at University of Toronto, Hospital for Special Surgery, and University of Pennsylvania. Acute management protocols reference corticosteroid regimens studied at Mayo Clinic and plasma exchange series reported by University of California Irvine and Brigham and Women's Hospital. Long-term immunomodulatory strategies draw on experience with agents evaluated in trials at NIH Clinical Center, Cleveland Clinic, and Karolinska University Hospital. Rehabilitation and multidisciplinary care pathways have been implemented in centers such as Johns Hopkins, Royal National Hospital for Rheumatic Diseases, and Rehabilitation Institute of Chicago.
Foundational discoveries trace to molecular and immunological research in the late 20th century from institutions including University of Freiburg, Institut de Biologie, and Rockefeller University. Subsequent translational studies from University of Pennsylvania, University of Cambridge, and Stanford consolidated the protein's relevance to human disease. Ongoing research programs at Broad Institute, Helmholtz Zentrum München, and Pasteur Institute focus on antigenic epitopes, animal models from European Molecular Biology Laboratory, and therapeutic antibody development pursued by biotech firms and academic spinouts affiliated with MIT and University of Oxford. International consortia including networks from European Commission-funded projects, National Institute for Health Research, and Wellcome Trust continue to coordinate multicenter studies.
Category:Proteins